First Tracks Biotherapeutics (TRAX) — Net Asset Momentum
First Tracks Biotherapeutics (TRAX) recorded a net asset momentum of -26.6% as of December 2025, with net assets of $287.49 Million USD. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. For live market cap and overall valuation, see market value of First Tracks Biotherapeutics.
YoY Momentum
Current Net Assets
Years of Data
Country
First Tracks Biotherapeutics Net Asset Momentum (2023–2025)
This chart tracks First Tracks Biotherapeutics's year-over-year net asset growth across 3 annual reporting periods from 2023 to 2025. The most recent momentum reading is -26.6%, with net assets of $287.49 Million USD as of December 2025. Check TRAX capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Annual Net Asset History for First Tracks Biotherapeutics (2023–2025)
The table below shows the complete annual net asset history for First Tracks Biotherapeutics from 2023 to 2025, covering 3 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. Check TRAX intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
| Year | Net Assets (USD) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | $287.49 Million | $330.55 Million | $43.05 Million | ▼ -26.6% |
| 2024 | $391.60 Million | $441.89 Million | $50.30 Million | ▼ -4.5% |
| 2023 | $409.85 Million | $444.11 Million | $34.26 Million | — |